Welcome to our dedicated page for Igm Biosciences SEC filings (Ticker: IGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IGM Biosciences, Inc. (IGMS) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents filed with the U.S. Securities and Exchange Commission. As a former Nasdaq-listed issuer, IGM Biosciences filed annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its clinical-stage biotechnology activities, financial position, collaboration revenues, operating expenses and risk factors related to its engineered IgM antibody platform.
Among the notable filings is a Form 8‑K dated July 1, 2025, in which IGM Biosciences reports entering into an Agreement and Plan of Merger with Concentra Biosciences, LLC and a merger subsidiary. This filing outlines the structure of the cash tender offer and subsequent merger, the treatment of common stock, stock options, restricted stock units and certain pre‑funded warrants, and the creation of contingent value rights tied to closing net cash and potential future dispositions of specified product candidates and intellectual property.
Investors researching IGMS can also review a Form 25 filed with the SEC, which notifies the removal of IGM Biosciences’ common stock from listing and registration on The Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. A later Form 15 filing certifies the termination of registration of the company’s common stock under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d), indicating that IGM Biosciences has deregistered its common stock and ceased ongoing Exchange Act reporting for that class of securities.
Stock Titan’s interface surfaces these filings in chronological order and can pair them with AI-powered summaries to highlight key points, such as changes in listing status, merger terms, cash thresholds, contingent value right mechanics and other material provisions. Users can quickly locate Forms 10‑K and 10‑Q for detailed historical financial and pipeline information, Forms 8‑K for material events, and the Form 25 and Form 15 that document the company’s transition from a publicly listed, reporting issuer to a wholly owned subsidiary following the Concentra transaction.
IGM Biosciences (IGMS) Form 4 filing – CFO Misbah Tahir reported a small automatic sale linked to restricted stock units (RSUs).
- Transaction details: On 06/16/2025, 1,522 common shares were sold at a weighted-average price of $1.1992 in multiple trades ranging from $1.17-$1.22.
- Purpose: Shares were sold solely to satisfy tax-withholding obligations arising from the vesting of RSUs (per footnote 1).
- Ownership post-sale: Tahir now directly owns 178,802 shares of IGMS common stock.
The filing does not disclose any open-market discretionary selling and therefore appears routine. The CFO retains more than 99% of his pre-sale position, suggesting ongoing alignment with shareholders. No derivative transactions or additional insider activity were reported.
IGM Biosciences Chief Executive Officer and Director Mary Beth Harler reported a Form 4 filing on June 28, 2025, disclosing a transaction that occurred on June 16, 2025.
Key transaction details:
- Sold 1,522 shares of Common Stock at a weighted average price of $1.1992 per share
- The sale was specifically to cover tax withholding obligations related to the vesting of restricted stock units
- Following the transaction, Harler maintains direct beneficial ownership of 338,181 shares
The transaction was executed through multiple trades with prices ranging from $1.17 to $1.22 per share. The filing was signed by Misbah Tahir via power of attorney on June 20, 2025.